news & events
Blog Style 07
Appointment of Dr Trevor Phillips to the Board of NovaBiotics
ABERDEEN 6 SEPTEMBER 2023. NovaBiotics, the clinical-stage biotechnology company announces the appointment of Dr Trevor Phillips to its board as Non-Executive Director. Trevor is a biotechnology leader who previously held board and C-level roles in pharma and Biotech...
Publication of NovaBiotics’ peer reviewed research on cysteamine’s antiviral and anti-inflammatory mechanisms
Publication of NovaBiotics’ research on the host-mediated anti-viral (including against coronaviruses and influenza) and anti-inflammatory mechanism of action of cysteamine, the active component of its advanced clinical stage NM001 and NM002 product candidates for...
Additional International Organization for Standardisation (ISO) accreditations for NovaBiotics
NovaBiotics adds ISO 14001: 2015 and ISO 45001: 2018 accreditations to its integrated quality management system. ISO 14001: 2015 Environmental Management Systems and ISO 45001:2018 Occupational Health & Safety Systems accreditation have now been awarded to...
NovaBiotics Announces Presentations of New Data for NM002 and NP339 at the European Congress of Clinical Microbiology & Infectious Diseases
New preclinical data further support the application of NM002 as novel anti-inflammatory-antimicrobial intervention in community acquired pneumonia and also data demonstrate the in vitro safety profile, fungal cell specificity and potential of NP339 in respiratory...
NovaBiotics to Present at the H.C. Wainwright BioConnect Conference
Aberdeen, January 4, 2022 – NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting-diseases, today announced that Dr Deborah O’Neil OBE, FRSE, Chief Executive Officer of NovaBiotics, will...
NovaBiotics Announces First Patient Enrolment into the Cysteamine Domain of REMAP-CAP
NovaBiotics’ NM002 (cysteamine bitartrate) Under Investigation in a Phase 3 Study for Community Acquired Pneumonia, Including COVID-19, Influenzas and Bacterial Pneumonias Aberdeen, December 8, 2021. NovaBiotics Ltd, a privately held clinical stage company developing...
NovaBiotics to Present New Data at Upcoming North American Cystic Fibrosis Conference
Highlights new insights into cysteamine’s mechanism of action against Pseudomonas aeruginosa and Burkholderia cenocepacia, further supporting cysteamine’s potential as an antimicrobial intervention in cystic fibrosis Aberdeen, October 29, 2021. NovaBiotics Ltd, a...
NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology
Highlights potential of novel antifungal’s immune-based approach to inhibit fungal pathogens Aberdeen, October 5, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases,...